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In a recent issue of Br J Clin Pharmacol, Smith et al.1 published an outstanding commentary titled “Dosing
will be a key success factor in repurposing antivirals for Covid-19.” They highlighted that the success in our
repurposing efforts will be dependent on “getting the dose right” for drugs which have been developed for
different indications and stressed some of the unique challenges of treating this particular disease. They
pointed the reader to lopinavir/ritonavir (LPV/r) as an example of a repurposed antiviral and the limited
experience of this drug regimen (and other treatments) in the elderly population with comorbidities—that is,
those most at risk from Covid-19. It is on the issue of comorbidities, polypharmacy, and drug-drug interactions
(DDIs) that we wish to comment.
Age-related comorbidities result in complex polypharmacy and an increased risk of DDIs.2 Furthermore,
physiological changes related to ageing may affect both pharmacokinetics (PK) and pharmacodynamics (PD)
thereby putting elderly patients at risk of inappropriate prescribing and adverse drug reactions. In the case
of LPV/r, particular attention needs to be focussed on PK interactions involving inhibition of CYP3A4 and
some transporters.2 To aid health care professionals managing LPV/r (and other antiretroviral) DDIs in
HIV patients, we developed the online resource www.hiv-druginteractions.org,3 which is extensively cited in
national and international treatment guidelines. However, in addition to PK interactions, LPV/r is known to
cause QT prolongation and is on the CredibleMeds listing4 for drugs with a possible risk of torsades de pointes
(TdP). Indeed, the drug label for LPV/r includes the warning to “avoid use with QT-prolonging drugs” because
of DDIs and effects on PR and QTc.5
Possibly of greater topicality at present is the risk of QT prolongation and TdP in Covid-19 patients given the
repurposed drugs chloroquine and hydroxychloroquine. This has been highlighted in recent cohort studies6,7
and in warnings from the EMEA8 and FDA.9
Patients given experimental COVID-19 therapies will often be clinically unstable with organ dysfunction,
and the development of toxicities from DDIs must be carefully considered. These very ill patients may not only
be receiving an experimental COVID drug with a known or possible risk of TdP as single agents or combined
(LPV/r, chloroquine, hydroxychloroquine, and azithromycin)4 but can have other risk factors for TdP such
as hypokalaemia, female gender, age > 70 years, and concomitant (e.g., some anaesthetics, muscle relaxants,
analgesics, antiarrhythmics, antibacterials, antipsychotics, and gastrointestinal agents) thereby potentially
increasing the risk of TdP.10 The CredibleMeds website classifies drugs into those with a known risk, a
possible risk, and a conditional risk of TdP. However, there is still the challenge of giving appropriate clinical
advice to guide the safe use of a COVID therapy and one or more co-medications in individual patients.
Having established prescribing resources for managing DDIs in other viral infections (with a database of
commentaries on >30 000 DDIs, with data systematically collected from medical and scientific literature,
information from drug regulatory authorities or expert opinion), to meet the challenge of the COVID pandemic
a similar resource is now available at www.covid19-druginteractions.org.11 DDIs are graded into four levels
and colour coded: (i) no clinically significant interaction expected (green); (ii) potential interaction likely
of weak relevance (yellow); (iii) potential interaction that may require close monitoring, alteration of drug
dosage or timing of administration (amber); and (iv) drugs should not be co-administered (red). It is made
clear that the decision to give or not give drugs is always the responsibility of the prescriber with many
other factors having to be considered such as age and electrolyte imbalance. In addition, since chloroquine
and hydroxychloroquine have very long half-lives (30–60 days), DDIs may occur even after discontinuing
treatment.9 Systematic medication review should aim at discontinuing unnecessary QT prolonging drugs
or finding alternatives devoid of QT risk. The use of decision support systems is important in effective
management of drug therapies in COVID patients.
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